Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Small Cell Lung Carcinoma 2Sarcoma 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Skin Neoplasms 1Resectable Hepatocellular Carcinoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Ichthyosis, X-Linked 1Glioma 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × ADI PEG20 × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT07389278 2026-02-05

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

University of California, San Francisco

Phase 1/2 Not yet recruiting
97 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡